Improvement of Personalized Cancer Care for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Through Digital Connection of Specialized Cancer Centers, Community Hospitals, Private Practices and Patients (DigiNet)

The aim of the DigiNet project is to improve the treatment of patients with advanced non-small cell lung cancer (NSCLC) in Germany. The project promotes the transfer of the latest scientific knowledge into standard care. The DigiNet project is based on the established precision medicine program, the National Network Genomic Medicine Lung Cancer (nNGM) in Germany, whereby every patient receives molecular diagnostics and personalized therapy information after the initial diagnosis. Within the framework of the DigiNet project, specialized academic centers will be digitally connected with practitioners via a shared project database. Furthermore, a committee of experts will monitor the course of treatment and will advise the practitioners in case of critical conditions. Additionally, patient-reported outcomes will be incorporated into the treatment.

开始日期2022-06-01

申办/合作机构

Barmer

[+8]

NCT05934032 / RecruitingN/AIIT

Registry of the National Network Genomic Medicine Lung Cancer (nNGM), Linking Data on Molecular Diagnostics, Clinical Characteristics, Treatment Patterns and Outcomes of Subjects With Non-Small Cell Lung Cancer in Germany

Registry of the national Network Genomic Medicine Lung Cancer (nNGM), linking data on molecular diagnostics, clinical characteristics, treatment patterns and outcomes of subjects with non-small cell lung cancer (NSCLC) from 23 specialized cancer centres and more than 400 general hospitals and oncological practices in Germany

开始日期2018-04-01

申办/合作机构

Universitätsklinikum Schleswig-Holstein

[+16]

100 项与 HELIOS Klinikum Emil von Behring GmbH 相关的临床结果

登录后查看更多信息

0 项与 HELIOS Klinikum Emil von Behring GmbH 相关的专利（医药）

登录后查看更多信息

414

项与 HELIOS Klinikum Emil von Behring GmbH 相关的文献（医药）

2024-09-01·Pneumologie

Ein Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. (DGP)

Article

作者: Kotz, Daniel ; Bauer, Torsten ; Raspe, Matthias ; Andreas, Stefan ; Blum, Torsten Gerriet ; Sohrab, Sebastian ; Pankow, Wulf ; Rupp, Alexander ; Rustler, Christa ; Windisch, Wolfram

2024-09-01·Zeitschrift für Gastroenterologie

S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)

Review

作者: Trebicka, Jonel ; Glanemann, Matthias ; Sterneck, Martina ; Aehling, Niklas F. ; Becker, Thomas ; Schnitzbauer, Andreas Anton ; Weismüller, Tobias ; Berg, Christoph P. ; Welker, Martin-Walter ; Bechstein, Wolf O. ; Lammert, Frank ; Engelmann, Cornelius ; Manekeller, Steffen ; Pascher, Andreas ; Kirchner, Gabriele ; Tacke, Frank ; Guba, Markus ; Trautwein, Christian ; Schlitt, Hans J. ; Pratschke, Johann ; Schott, Eckart ; Settmacher, Utz ; Klein, Ingo ; Neumann, Ulf ; Schmidt, Hartmut H. ; Strnad, Pavel ; Bruns, Tony ; Berg, Thomas ; Braun, Felix ; Seehofer, Daniel ; Canbay, Ali E.

2024-08-01·European Journal of Cancer

Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations

Article

作者: Wölwer, Christina Bianca ; Groß, Thorben ; Gatteloehner, Stefan ; Merkelbach-Bruse, Sabine ; Jeratsch, Ulli ; Keymel, Stefanie ; Kauffmann-Guerrero, Diego ; Scheffler, Matthias ; Wiesweg, Marcel ; Kulhavy, Jonas ; Joosten, Maria ; Oeser, Katharina ; Demes, Melanie-Christin ; Tufman, Amanda ; Wolf, Juergen ; Hummel, Horst-Dieter ; Schubart, Christoph ; Zehaczek, Melanie ; Kollmeier, Jens ; Kron, Anna

BACKGROUNDThis study provides comparative evidence of the selective MET inhibitor capmatinib versus standard of care (SOC) in first-line (1 L) and second-line (2 L) non-small cell lung cancer (NSCLC) patients with METex14 mutations in German routine care.METHODSSOC data were collected from German routine care via retrospective chart review. Analyses were conducted as naive and propensity score adjusted (PSA) comparisons to capmatinib-treated patients within the GEOMETRY mono-1 trial. Effectiveness endpoints included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), time to CNS progression (CNSprog), and exploratory safety endpoints.RESULTSThe SOC arm included 119 patients in 1 L and 46 in 2 L versus 60 patients in 1 L and 81 in 2 L treated with capmatinib, with balanced baseline characteristics after PSA. In 1 L, the naive comparison showed a significant benefit of capmatinib versus SOC for OS (median: 25.49 vs 14.59 months; HR 0.58; 95 % CI 0.39-0.87; P = 0.011), PFS (median: 12.45 vs 5.03 months; HR: 0.44; 95 % CI: 0.31-0.63; P < 0.001), and ORR (event rate: 68.3 vs 26.9 %; RR 2.54; 95 % CI 1.80-3.58; P < 0.001). In 2 L, OS, PFS, and ORR showed positive trends favoring capmatinib over SOC. Capmatinib treatment in the 1 L and 2 L led to significant benefit in CNSprog. PSA analyses showed consistent results to naive analysis. Exploratory safety endpoints indicated a manageable safety profile for capmatinib.CONCLUSIONSThe present study demonstrates the important role of capmatinib in providing robust clinically meaningful benefit to patients with NSCLC harboring METex14 mutations and its significant role in preventing the development of brain metastases.

100 项与 HELIOS Klinikum Emil von Behring GmbH 相关的药物交易

登录后查看更多信息

100 项与 HELIOS Klinikum Emil von Behring GmbH 相关的转化医学

登录后查看更多信息